Bloomage Biotechnology Corp Ltd

Ernst & Young recently released a report pointing out that by 2032, the world's top 25 biopharmaceutical companies are expected to face a potential growth gap of over 370 billion US dollars. The status of Chinese innovative drugs has changed markedly, with the proportion of China-related biopharmaceutical collaboration deals in the potential value of European and American collaboration deals rising from about 8 percent in 2020 to 34 percent in 2025. As of July 30, 2026, the constituents of the Shanghai Stock Exchange STAR Board Biomedical Index were mixed, with Bloomage Biotechnology leading gains at 6.44 percent. The STAR Board Medical ETF from China Asset Management has seen net inflows for seven consecutive days, attracting a total of 113 million yuan.

As of 2:45 p.m. on July 22, 2026, constituents of the SSE STAR Board Biomedical Index were mixed. BrightGene led gains with 12.20%, Medicilon rose 5.98%, Bloomage Biotechnology gained 5.40%, while Hotgen Biotech led declines. The Sci-Tech Innovation Board Healthcare ETF Huaxia last traded at 1.05 yuan, with intraday turnover of 15.98% and turnover of 61.5624 million yuan. Average daily turnover over the past week was 77.0437 million yuan. In news, as of July 20, 94 of the 504 A-share pharmaceutical and biotech companies had disclosed earnings forecasts, a disclosure rate of 18.65%. Among them, 55 companies reported positive net profit growth for the first half of the year, accounting for 58.51%. The innovative drug industry chain and the CXO sector performed notably well. Tianfeng Securities pointed out that in the first half of 2026, there were 621 global transactions, of which 90 involved Chinese molecules, accounting for 14.5%. The total global transaction value reached 302.893 billion US dollars, of which Chinese molecules accounted for 95.905 billion US dollars, or 31.66%. The influence of Chinese innovative molecules is steadily growing worldwide. The Sci-Tech Innovation Board Healthcare ETF Huaxia closely tracks the SSE STAR Board Biomedical Index, which selects 50 listed companies in the biomedical and related fields with larger market capitalizations from the STAR Board as samples. The top ten weighted stocks account for a combined 51.84%.